May 2, 2018 / 11:40 AM / 3 months ago

BRIEF-Kura Oncology Announces New Patent For Tipifarnib In Hematologic Malignancies

May 2 (Reuters) - Kura Oncology Inc:

* KURA ONCOLOGY ANNOUNCES NEW PATENT FOR TIPIFARNIB IN HEMATOLOGIC MALIGNANCIES

* KURA ONCOLOGY INC - BIOMARKER-ENRICHED DATA FROM ONGOING PHASE 2 TRIALS OF TIPIFARNIB IN HEMATOLOGIC MALIGNANCIES EXPECTED IN H2 OF 2018

* KURA ONCOLOGY INC - PATENT EXPANDS PROTECTION FOR TIPIFARNIB IN U.S., PROVIDES EXCLUSIVITY IN CERTAIN CXCL12-EXPRESSING CANCERS TO 2037 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below